FIELD: medicine.
SUBSTANCE: stimulating neovascularisation of retina and optic nerve is ensured by the intravitreal introduction of an aqueous solution of recombinant human vascular endothelial growth factor in the amount 0.05-0.1 ml to experimental animals - rabbits. A dose of said agent is administered intermittently. On the 1st and 3rd days of experiment, the dose is 3 mcg, on the 7th and 11th days - 1.5 mcg, on the 15th day - 1.0 mcg, and on the 24th day - 5.0 mcg.
EFFECT: while being technically available and easily reproducible, the method provides the sequential development of eye grounds changes with a precise dependence from a dose administered that allows to follow all the stages of a pathological process leading to posterior eye vascularisation.
1 ex, 9 dwg
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR SIMULATING ANTERIOR SEGMENT NEOVASCULARISATION IN RATS | 2012 |
|
RU2488891C1 |
METHOD FOR SIMULATING DIABETIC MACULAR NEOVASCULARISATION | 2012 |
|
RU2504844C1 |
METHOD OF TREATING ATROPHIC AGE-RELATED MACULAR DEGENERATION | 2009 |
|
RU2521338C9 |
METHOD FOR TREATING ATROPHIC AGE RELATED MACULAR DEGENERATION | 2009 |
|
RU2668371C2 |
INTEGRIN RECEPTOR ANTAGONISTS AND USE THEREOF | 2012 |
|
RU2721907C2 |
AGENT INHIBITING ANGIOGENESIS IN VISUAL ORGAN DISEASE | 2001 |
|
RU2177801C1 |
METHOD OF TREATING LATENT SUBRETINAL NEOVASCULAR MEMBRANES | 2009 |
|
RU2395318C1 |
METHOD OF TREATING WET AGE-RELATED MACULAR DEGENERATION OF RETINA WITH USING CELL TRANSPLANTATION | 2011 |
|
RU2467727C2 |
PHARMACEUTICAL ANTIANGIOGENIC COMPOSITION FOR TREATING EYE DISEASES | 2013 |
|
RU2526825C1 |
METHOD FOR COMBINED TREATMENT OF SECONDARY NEOVASCULAR OPEN-ANGLE GLAUCOMA | 2022 |
|
RU2786145C1 |
Authors
Dates
2010-12-27—Published
2009-06-26—Filed